This is a Phase 3 research study looking into the effectiveness and safety of a new investigational medication (itepekimab). We want to find out if it can help reduce the number of flare-ups (also known as exacerbations) that people with COPD have over the course of a year.
Itepekimab is a human monoclonal antibody (a type of protein) that blocks the activity of
interleukin-33 (IL-33) in your body (interleukins are proteins that stimulate the immune
response and can cause inflammation).
IL-33 may play a role in COPD, and blocking the effects of IL-33 may improve COPD symptoms.
To date, itepekimab has been studied in 7 studies (tests) in humans: 5 completed studies
and 2 ongoing studies. Of the 5 completed studies:
This study will compensate each participant $100.00 for every completed study visit until the end of the study or withdrawal.
Being involved in our clinical trial won’t cost you anything. All trial-related costs above your usual care will be free. And don’t let travel costs put you off – we’re happy to talk about covering any expenses you need to take part in the study.